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Abstract
Background Bone-targeted agents (BTAs) used for the
prevention of skeletal-related events (SREs) associated
with metastatic bone disease possess different attributes
that factor into treatment decisions.
Objective The aim of this study was to evaluate prefer-
ences of patients, caregivers, and nurses for features of
BTAs used to prevent SREs in patients with a self-reported
physician diagnosis of bone metastasis from solid tumors.
Methods Patients (n = 187), primary caregivers
(n = 197), or nurses (n = 196) completed a web-enabled
discrete-choice experiment (10-question survey) in which
they chose between pairs of hypothetical profiles of BTAs.
Each profile was defined by six key treatment attributes,
including efficacy and safety (two each) and route/fre-
quency of administration and cost (one each). The relative
importance of treatment attributes and levels was
estimated.
Results The most important treatment attribute for
patients and nurses was out-of-pocket cost, and for care-
givers, treatment-related risk of renal impairment. Risk of
renal impairment was the second most important attribute
for patients and nurses, while time until first SRE was the
third most important attribute for all respondents. For
nurses, risk of osteonecrosis of the jaw was least important,
and for patients and caregivers, mode of administration was
least important.
Limitations Respondents considered hypothetical medi-
cations; therefore, their decisions may not have the same
consequences as actual decisions.
Conclusions The perspectives of patients, caregivers, and
nurses are integral when making treatment decisions about
BTAs to prevent SREs associated with solid tumors.
Identifying the relative importance of attributes of BTAs
will aid in the proper selection of therapy in this setting,
which may improve patient outcomes.
Electronic supplementary material The online version of this
article (doi:10.1007/s40271-015-0158-4) contains supplementary
material, which is available to authorized users.
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Key Points for Decision Makers
Little is known about preferences and trade-offs
among important stakeholders (ie, patients, nurses,
and caregivers) for treatment attributes for bone-
targeted agents used to manage metastatic bone
disease.
A web-enabled discrete-choice experiment identified
that the most important treatment attributes for
patients and nurses were, in order of importance, out-
of-pocket cost to patients, risk of renal impairment,
and time until first skeletal-related event; for
caregivers, the order of importance was risk of renal
impairment, out-of-pocket cost to patients, and time
until skeletal-related event.
Understanding the perspectives of patients,
caregivers, and nurses would help optimize treatment
selection of bone-targeted agents for metastatic bone
disease and ultimately improve patient outcomes.
1 Introduction
Metastatic bone disease is a chronic condition commonly
associated with skeletal complications (e.g. spinal cord
compression, radiation to the bone, surgery to bone, and
pathologic fractures), collectively referred to as skeletal-
related events (SREs) [1–3]. Approximately 70 % of
patients with advanced breast or prostate cancer show
evidence of bone metastasis, making bone the most com-
mon site of metastases for these cancers [1, 4–7]. In one
study of women with metastatic breast cancer,[80 % of
those with bone-limited metastases developed SREs [3].
SREs affect patients’ ability to perform basic daily tasks
necessary for normal functioning, cause pain, and impair
overall quality of life while increasing mortality [4, 8, 9].
Often patients experience depression and anxiety associ-
ated with SREs, especially those who receive radiation to
the bone [8]. The economic burden placed on the health-
care system by SREs is also substantial, with the mean
SRE-related cost (in US dollars) per patient estimated to
range from approximately $12,000 to $14,000, and the
costs per episode ranging from approximately $4000 to
$64,000 [10–13].
Current treatment options for SREs include bisphos-
phonates, such as zoledronic acid [14, 15] and, more
recently, the monoclonal antibody denosumab [16].
Although denosumab was shown to have superior efficacy
versus zoledronic acid in delaying the onset of SREs [17–
19], other factors such as type/frequency of treatment-
emergent adverse events, mode of administration, and out-
of-pocket costs may also factor into treatment decisions
[20, 21]. The influence of these various attributes on
treatment preference may differ between patients and those
responsible for their care. Indeed, in the current era of
shared decision making in the oncology setting, clinicians
should ensure treatments deliver the best quality of life
possible for their patients, with minimal post-treatment
decisional regrets [22]. Evidence suggests patient prefer-
ences and beliefs about treatments for cancer are not nec-
essarily in agreement with those of their physicians [23–
27]. However, nurses may be better positioned to help
patients and their caregivers with treatment decisions and
improve communication with physicians and other mem-
bers of a patient’s healthcare team [28]. Furthermore,
oncology nurses work in a range of roles and settings, such
as nurse-run clinics, chemotherapy prescreening, and
management of symptoms such as pain [29]. Therefore it is
also important to understand their treatment preferences.
The discrete-choice experiment (DCE) is commonly used
to assess preferences for medical interventions [30]. DCE
data have previously been gathered to determine physi-
cians’ perspectives [31], but complementary information
from patients, caregivers, and nurses is lacking. The main
objective of this study was to quantify preferences, using
DCE methodology, of patients, caregivers, and nurses for




The primary objective of this study was to quantify the
preferences of patients, primary caregivers, and nurses in
the US for attributes associated with treatments for the
prevention of SREs in patients with bone metastases from
solid tumors. A secondary objective was to estimate the
proportion of participants who would choose given treat-
ment profiles with characteristics similar to those of
denosumab or zoledronic acid, the two main treatment
options for SRE prevention in the US.
2.2 Study Sample
Patients included were C18 years of age and had a self-
reported physician diagnosis of bone metastases from solid
tumors. Caregivers were unpaid individuals taking care of
patients with bone metastases from solid tumors. Nurses
included in the study were involved in treating patients
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with bone metastases from solid tumors. Upon recruitment,
all respondents provided online informed consent.
A survey research company (Harris Interactive, Inc.,
Rochester, NY, USA) recruited all of the respondents from
existing online panels of patients who had previously been
chosen and invited to participate in other health surveys.
The survey research company coordinated the 25-min
online survey between December 2012 and January 2013.
The study materials were reviewed by the Office of
Research Protection and Ethics at RTI International (Re-
search Triangle Park, NC, USA) and were approved by
their Institutional Review Board.
2.3 Discrete-Choice Experiments
DCEs compare and quantify preferences of various treat-
ment characteristics/outcomes to the study population
(patients, caregivers, and nurses in our study) [30, 32, 33].
There are a number of assumptions associated with DCEs
[34]: (1) a medical treatment can be described by its
characteristics or attributes (e.g. risk of adverse effects); (2)
these attributes can be further specified by different levels
of that characteristic (e.g. attribute levels for risk of adverse
effects, 10 %, 20 %, 30 %, etc.); and (3) an individual’s
preference for a treatment can be determined by the levels
of those attributes (preferences for treatments were mod-
eled as a function of the attribute levels). To evaluate the
relative importance of treatment attributes and trade-offs in
DCEs, respondents are presented with a series of questions
and are asked to choose between two alternative hypo-
thetical treatments with different combinations of attribute
levels.
2.4 Survey Instrument
A web-enabled survey was used to elicit preferences and
collect demographic information (e.g. age, sex, and
employment status) and information about the respondents’
experience with bone metastases treatment. Two survey
instrument versions were created that differed in the
wording used to describe treatment attributes: a simplified
version for patients and caregivers, and a version for nurses
using standard medical terminology. The overall meaning
of the attributes was the same for both versions. The study
followed good practices for design and administration of
DCEs [35]. The survey development process and survey
questions are described in more detail in the appendix in
the electronic supplementary material.
The six treatment attributes (Table 1) assessed in this
survey were chosen after reviewing prescribing informa-
tion and medical literature and consulting with clinical
experts. The attributes included time until first SRE, time
until 2-point increase in pain on the Brief Pain Inventory
(BPI), risk of osteonecrosis of the jaw (ONJ) each year, risk
of a 0.5-mg/dL increase in baseline creatinine each year
(risk of renal impairment), mode of administration and
Table 1 Attributes and levels
for the choice questions
Attributea Levels
Time until first SRE (time until you/the patient have a




Time until a 2-point increase in pain on the BPI (time until




Risk of ONJ each year (chance of a problem with your/the
patient’s teeth and/or jawbone each year because of the medicine)
None
1 of 100 (1 %)
5 of 100 (5 %)
Risk of 0.5-mg/dL increase in baseline creatinine each year
(chance of kidney problems because of the medicine each year)
None
4 of 100 (4 %)
10 of 100 (10 %)
Mode of administration and frequency (how you/the patient
takes the medicine)
Injection every 4 weeks
15-min infusion every 4 weeks
120-min infusion every 4 weeks
Out-of-pocket cost to the patient each month (personal cost to





BPI Brief Pain Inventory, ONJ osteonecrosis of the jaw, SRE skeletal-related event
a Attributes in parentheses represent those for patients and caregivers
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frequency, and monthly out-of-pocket cost to the patient.
Each of the attributes had three or four levels, and the
levels were designed to encompass the range of outcomes
observed in current clinical practices, as well as the range
over which patients, caregivers, and nurses are willing to
accept tradeoffs among attributes. Only attributes charac-
terizing treatment risks (i.e. risk of ONJ and risk of
increase in creatinine levels) were presented as proba-
bilistic attributes because they are not expected to occur in
all patients who start treatment. The choice scenarios in the
DCE were prepared to address a specific preference-sen-
sitive clinical decision, in which some degree of efficacy is
obtained but a risk of adverse events is present, and
stakeholders need to determine whether the possibility of
facing adverse events is worth pursuing treatment. The
choice scenario also excluded the possibility of opting out
of treatments as a way to require that respondents provide
information on the tradeoffs designed into the treatment
profiles in each choice question. This approach maximizes
the preference information collected with regard to attri-
butes and attribute levels shown.
The surveys were pretested to assess clarity and appro-
priateness of the descriptive information, as well as the
relevance and thoroughness of the attributes and levels.
The pretesting involved open-ended face-to-face or phone
interviews with 15 patients, 11 caregivers, and 6 nurses in
the US. The study team also included cheap-talk text to
reduce the likelihood that respondents ignored the specific
attribute levels presented to them in the choice questions
[36, 37].
Respondents answered 10 choice questions, choosing
between pairs of hypothetical medication profiles (Fig. 1).
Patients were asked to choose a hypothetical treatment
profile for themselves, and caregivers were asked to choose
a hypothetical treatment profile for the patient they were
caring for. Because nurses see patients at different stages of
the disease in their practice, two profiles—one of a typical
breast cancer patient and one of a typical prostate cancer
patient—were provided to nurses, and they were asked to
make hypothetical treatment decisions based on these
profiles (electronic supplementary Table S1); descriptions
were provided to nurses to help illustrate typical patients.
Medication Feature
Time until first SRE 28 months
shtnom6shtnom3
18 months
Time until a 2-point increase
in pain on the Brief Pain Inventory
Mode of administration and frequency 120-minute infusion every 4 weeks
051$033$
Injection every 4 weeks
Out-of-pocket cost to the patient
each month
Which would you choose?
5 out of 100 (5%)
NoneRisk of osteonecrosis
of the jaw each year
)%01(001fotuo01)%4(001fotuo4
Risk of 0.5-mg/dL increase in baseline 
creatinine each year
Medication A Medication B
Fig. 1 Hypothetical medication choice example. Comparison between two hypothetical pharmacologic therapies for SREs (medications A and
B) presented to the nurses in the study. SRE skeletal-related event
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This practice was intended to reduce bias from the nurses’
own experiences. A main-effects D-efficient experimental
design was prepared with a commonly used algorithm in
SAS version 9.3 (SAS Institute, Cary, NC, USA) and in
accordance with good research practices to optimize the
statistical properties of the design, given the number of
attribute levels and the complexity of the task layout [38],
and included four sets of nine unique choice questions and
one repeated choice question (10 questions in total for each
survey version). The total balanced the number of ques-
tions needed for an identifiable model of preferences and
the number of questions most of our pretest participants
stated they could answer reliably before the instrument
became overly burdensome. Questions avoided implausible
or dominated treatment profiles (treatments that were
unambiguously worse than the alternatives), and all levels
varied across attributes. Each respondent was randomly
assigned to one set.
2.5 Statistical Analysis
We reviewed time to completion of the survey and
response variability as a way to gauge the validity of par-
ticipants’ responses. Respondents who completed the sur-
vey in less than 6 min or those who always picked
‘medicine A’ or ‘medicine B’ in the choice questions were
eliminated. We interpreted these responses as a strong
indication that respondents were not paying attention to the
information presented in the choice questions included in
the survey.
Descriptive statistics, including respondents’ demo-
graphics and type of cancer (patients/caregivers), and
clinical experience with bone metastasis (nurses) were
reported. The respondents’ answers to the choice questions
in the survey were modeled using a random parameters
logit (RPL) model—a statistical model for examining dis-
crete choices that provides estimates of mean preference
weights (relative strength of preference or relative impor-
tance) for individual treatment attribute levels [39, 40].
Choice data from patients and caregivers were pooled to
estimate a model that constrained preferences between the
two groups to be the same for attributes for which no
statistical differences were found between the two groups.
Heterogeneity in the variability of responses between
groups is known as scale heterogeneity and can limit the
ability to pool data. We controlled for scale heterogeneity
between patients and caregivers by estimating a group-
specific random effect in the RPL model. Because logit
models permit only the estimation of the variance of one
group relative to that of another group, we normalized the
variance of caregivers to 1 and estimated the variance of
patients relative to the variance of caregivers. Choice data
from nurses were analyzed in a separate model. All
attribute levels were assumed to be normally distributed
across respondents in each population. Other studies have
used a similar modeling technique [32, 41].
Estimated preference weights were used to calculate the
predicted proportion of participants who would choose
given treatment profiles. By applying the preference
weights (relative importance) to the attribute levels inclu-
ded in each profile, we were able to predict the proportion
of respondents who would select one of several drug pro-
files as a way to gauge respondents’ preferences for bun-
dles of attribute levels, not just the pairwise comparisons of
specific attribute-level preferences that are possible via
comparison of preference weights. As a way to make this
bundled evaluation of relative preferences more meaning-
ful, we evaluated the likelihood of choice for treatment
options that resembled currently available treatments. The
profiles of attributes for denosumab and zoledronic acid
used for this assessment were derived from prescribing
information [15, 16] and clinical trial data [42].
3 Results
3.1 Response Rate and Sample Characteristics
Information on the recruitment and disposition of respon-
dents is presented in electronic supplementary Fig. S1. The
number of patients, caregivers, and nurses responding to
the initial invitation to participate was 2340/97,500
(2.4 %), 461/17,800 (2.6 %), and 425/14,570 (2.9 %),
respectively. Of those eligible to participate, 87.0 % (200/
230) of patients, 80.0 % (200/250) of caregivers, and
77.5 % (200/258) of nurses completed the survey. A total
of 13 patients, three caregivers, and four nurses were
excluded from the final analysis because they always chose
the same answer in the choice questions (indicating a lack
of attention to the choice questions), leaving totals of 187,
197, and 196 respondents in the analysis for the respective
groups. The cooperation rate was 81 % (187/230) for
patients, 76 % (196/258) for nurses, and 79 % (197/250)
for caregivers.
Electronic supplementary Table S2 shows the demo-
graphic characteristics of the eligible patients and care-
givers included in the analysis. The mean age of the
patients was 43 years, 58 % were men, 44 % were
employed, 34 % had breast cancer, 45 % were diagnosed
with bone metastases\1 year before the study, and 75 %
were currently taking treatment to delay complications of
bone metastases. The mean age of caregivers was 36 years,
61 % were men, 67 % were employed, and 30 % were
caring for a patient with breast cancer. Approximately
73 % of patients and 74 % of caregivers noted a skeletal
complication secondary to metastases. Electronic
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supplementary Table S3 shows the demographic charac-
teristics of the nurses included in the analysis. Fifty-five
percent were 46 years of age or older, 80 % were regis-
tered nurses, 76 % were oncology nurses, 55 % were
hospital-based staff, and 47 % treated more than 10
patients with bone metastases from solid tumors each
week.
3.2 Relative Importance Estimates
The mean preference weights for all attribute levels are
shown in Fig. 2 and electronic supplementary Table S4.
Across the three populations, the mean preference weights
were consistent with the natural ordering of the levels of
the represented attribute (i.e. better clinical outcomes were
preferred to worse clinical outcomes, lower out-of-pocket
cost was preferred to higher out-of-pocket cost, etc.). The
lines connecting the data points (mean preference weights)
in Fig. 2 indicate the relative strength of the preference for
the most- and least-preferred attribute levels. The greater
the vertical distance between data points for a particular
attribute, the greater the importance of having a treatment
with that attribute over the attribute ranges and levels
included in the survey. These results form the basis for the
data in Table 2, which lists the attributes’ relative impor-
tance in decreasing order by respondent group. The order
of importance varied by respondent type. The three most
important treatment attributes for patients and nurses were
out-of-pocket cost to patients, treatment-related risk of
renal impairment, and how long treatment delays time to
first SRE. For caregivers, the risk of treatment-related renal
impairment was a more important treatment attribute than
out-of-pocket cost to patients.
The relative importance of changes among the inter-
mediate levels of an attribute is also reflected in the data
lines in Fig. 2 (i.e. the less vertical distance between the
data points or mean preference weights, the less important
a change in level for that attribute is for the respondent).
For example, patients and caregivers perceived relatively
little difference between treatments administered via a
15-min infusion every 4 weeks and treatments adminis-
tered via 120-min infusion every 4 weeks (Fig. 2a). Simi-
larly, nurses perceived no difference between treatments
when the risk of ONJ was reduced from 1 % to no risk
because nurses perceived no difference between these two
ONJ risk levels (Fig. 2b). Additional information on the
RPL model can be found in electronic supplementary
Table S5.
Preference estimates from the DCE survey results (not
including cost) and the profiles of actual product attributes
were used to calculate the predicted proportion of partici-
pants who would choose a given treatment profile (re-
spondents were not directly asked about their preference
for existing treatments). Based on these preference esti-
mates, the model predicted 75 % of patients, 78 % of
caregivers, and 96 % of nurses would prefer a drug therapy
with attributes similar to those of denosumab over a drug
therapy with attributes similar to those of zoledronic acid
(Table 3). Given that participants were not allowed to opt
out of treatment in the choice questions, respondents were
not allowed to reveal whether they preferred no treatment
over the treatment alternatives in each choice question. For
this reason, it is important to note that the predicted pro-
portion of respondents who would select a given drug
profile is only a measure of preference (i.e. likelihood of
choice) and cannot be considered a demand analysis for
any of these treatments.
4 Discussion
The results of our analysis show that out-of-pocket cost of
bone-targeted agents (BTAs) for bone metastases was an
important concern for all groups of respondents. For
patients and nurses, this was the most important attribute,
whereas caregivers considered it the second most important
attribute. This result has implications for the use of older
therapies versus newer therapies that may have higher drug
acquisition costs [20, 21]. It also underscores the impor-
tance of assistance programs that facilitate patient access to
lower-cost medications. Improved communication regard-
ing available programs is important to facilitate patients’
access to therapies. Patients and caregivers should be
proactive in inquiring about these programs; however, the
existence of such programs is not always apparent to
patients and their caregivers. Furthermore, older patients
may lack the knowledge or resources to search for such
programs online or elsewhere [28]. Nurses often have more
information than physicians regarding drug assistance
programs and may also be more attuned to patients’
financial concerns and, thus, would be expected to play an
important role in this area, especially with regard to edu-
cating patients and caregivers regarding program avail-
ability. In addition, the results of this study provide nurses
with information regarding patients’ and caregivers’ treat-
ment preferences with respect to bone-targeting agents and,
because patients’ and nurses’ preferences aligned well in
our study, increase their ability to provide patient-driven
treatment decisions.
For patients and nurses, the second most important
attribute after out-of-pocket cost was risk of renal impair-
ment, whereas for caregivers the risk of renal impairment
was the most important attribute. Results from a recent
DCE that evaluated patients’ preferences for bone metas-
tases treatment in France, Germany, and the UK also
showed that time until first SRE and risk of renal
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ab
Fig. 2 a Patient and caregiver
and b nurse preference weights
for treatment attributes. Vertical
bars surrounding mean
preference weight point
estimates denote the 95 % CI.
Nonoverlapping 95 % CIs
indicate statistically different
mean estimates for an attribute.
SRE skeletal-related event, CI
confidence interval
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impairment were important attributes for BTAs (out-of-
pocket costs were not evaluated) [43]. This is consistent
with the results for patients in our study in that risk of renal
impairment and time until first SRE were the most
important attributes after out-of-pocket costs. Another
recent DCE conducted with US physicians also reported
out-of-pocket costs as the most important attribute for
BTAs in this setting, followed by time until first SRE and
risk of renal impairment [31].
It is plausible to speculate that differences in the order of
important treatment attributes amongst our study popula-
tions reflect different priorities—patients are directly
affected by the reduced quality of life that accompanies
SREs, and caregivers and nurses may be more concerned
with avoiding treatment toxicities that may reduce survival.
Indeed, data support that patients may prefer quality of life
to added survival [41, 44, 45]. Recent data from a DCE in
patients with advanced prostate cancer from the UK and
Sweden showed more patients would choose to receive
BTAs to delay bone metastases as the number of months’
delay of bone metastases increased and the associated risk
of ONJ decreased [46]. However, a majority of patients
(52 % for the UK and 60 % in Sweden) in that study would
still choose a treatment that minimally delayed bone
metastasis (by 5 months, the lowest-choice question level),
even at a relatively high risk for ONJ (9 %; the highest-
choice question) [46]. Moreover, 74 % of patients from the
UK and 85 % of patients from Sweden indicated they
would forego at least 3 months’ survival time to avoid an
SRE [46]. Therefore, when making treatment decisions,
healthcare providers cannot assume patients value survival
above other considerations, underscoring the importance of









1 (most) Out-of-pocket cost to the
patient each month
10.00 Risk of 0.5-mg/dL
increase in baseline
creatinine each year
13.87 Out-of-pocket cost to the
patient each month
10.00
2 Risk of 0.5-mg/dL
increase in baseline
creatinine each year
6.01 Out-of-pocket cost to the
patient each month




3 Time until first SRE 2.65 Time until first SRE 4.86 Time until first SRE 4.68
4 Time until a 2-point
increase in pain on the
BPI
1.69 Time until a 2-point
increase in pain on the
BPI
3.10 Time until a 2-point
increase in pain on the
BPI
3.65
5 Risk of ONJ each year 1.16 Risk of ONJ each year 2.13 Mode of administration 3.32
6 (least) Mode of administration 1.13 Mode of administration 2.08 Risk of ONJ each year 1.70
BPI Brief Pain Inventory, ONJ osteonecrosis of the jaw, SRE skeletal-related event
a The numbers in the ranking table had to be rescaled to reflect the importance of each attribute relative to the overall importance of out-of-
pocket cost (where the importance of increasing treatment from $25 to $330 is set to be 10). Without this rescaling, the ranking numbers cannot
be compared across populations
Table 3 Predicted choice probabilities
Attribute Characteristics similar to denosumaba Characteristics similar to zoledronic acida
Time until first SRE, months 27.7 19.5
Time until worsening of pain, months 6.6 4.7
Risk of ONJ, % 1.8 1.3
Risk of renal impairment, % 0 9.3
Mode of administration Injection every 4 weeks 15-min infusion every 4 weeks




ONJ osteonecrosis of the jaw, SRE skeletal-related event
a Values derived from prescribing information for denosumab [16] and zoledronic acid [15]
b Values represent the predicted probability that each alternative with its associated attributes would be chosen if these profiles represented the
only available treatment options
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eliciting treatment and outcome preferences from patients.
Similarly, a recent DCE study calculated the willingness to
pay (WTP) for various end-of-life treatments. The patients’
WTP to extend their life by up to 1 year was not greater
than their WTP to avoid severe pain. In addition, caregivers
had a higher WTP to extend the patient’s life [45].
This study also indicated that most patients, caregivers,
and nurses preferred a hypothetical drug therapy with attri-
butes similar to those of denosumab over a hypothetical drug
therapy with attributes similar to those of zoledronic acid
(based on five clinical attributes included in the study
design, excluding out-of-pocket cost), in keeping with the
preference indicated by the recent DCE of US physicians
[31]. This treatment preference was largely driven by
improved efficacy and reduced risk of renal toxicity attri-
butes. Out-of-pocket costs were not included in the predicted
choice probabilities assessment because, in practice, out-of-
pocket costs vary by insurance coverage and use of patient
assistance programs. In the recent abovementioned patient
DCE study, more than 90 % of patients from France, Ger-
many, and the UK also strongly preferred an agent with
characteristics similar to those of denosumab over agents
with characteristics similar to those of the bisphosphonates
zoledronic acid, clodronate, and pamidronate [43], consis-
tent with results for US patients in our study.
A number of study limitations should be considered.
Because respondents were asked to consider hypothetical
medications, their decisions may not have the same clinical,
financial, and emotional consequences of actual decisions.
We have attempted to minimize this possible bias by striving
to make the hypothetical choice mimic, as closely as pos-
sible, real-world tradeoffs by verifying the attributes inclu-
ded in the DCE survey through open-ended interviews
during testing. In addition, Internet surveys represent a
convenience sample, and therefore they may not represent
the general population. Furthermore, low response rates
suggest that caution should be taken when generalizing these
results to the population of patients, caregivers, and nurses
who would conceivably be involved in the decisions eval-
uated in this study. Because demographic data for individ-
uals not included in the final analysis were not collected, it
cannot be determined whether the recruitment procedure
introduced selection bias. However, the total number of
participants was in line with our prespecified criteria.
Another general limitation of preference-elicitation
studies, and DCEs among them, is that no power calcula-
tion can be conducted to determine minimum sample size
for hypothesis testing without prior information on
respondents’ expected preferences. Most published choice
experiments have a sample size from 100 to 300 respon-
dents [30]; however, minimum sample size depends on a
number of criteria, including the question format, com-
plexity of the choice task, desired precision of the results,
and need to conduct subgroup analyses [47]. Moreover,
although we did consult with clinical experts regarding the
survey, we did not perform external validation; conse-
quently, it is unknown to what extent our results agree with
real-world choices. The preference comparisons presented
here were aimed at evaluating the relative importance of
the attributes and attribute levels in the choice questions to
contrast each group’s perspective on treatments and their
features rather than formally testing for consistency of
preferences across groups.
The results of this study underscore the importance of
establishing patient (and/or caregiver) treatment prefer-
ences and cost considerations, information that can help
nurses and other clinicians facilitate communication
between patients and providers. Although physicians are
primary sources of information regarding bone metastases
and associated treatments to patients with solid tumors,
there is a gap between physician assumptions about patient
knowledge of bone health and patient perceptions [27].
Physicians tend to overestimate patient education and
understanding of the diagnosis and treatment explanations,
and these discordances are associated with patient dissat-
isfaction with their interactions with physicians [48].
Patients and caregivers value family involvement in cancer
treatment decision making, although there is often dis-
agreement on who should take the decisional leadership
[49]. Oncology nurses often have more opportunities to
spend time with patients and their families than physicians
do (e.g. during chemotherapy infusions and radiation
treatments), and therefore are well positioned to elicit a
patient’s preferred level of participation in decisions about
treatment and to encourage patients to share their prefer-
ences with their physicians [50].
5 Conclusions
Our study showed patients, caregivers, and nurses gener-
ally had clear preferences for drug characteristics of BTAs
used to manage metastatic bone disease. Improved under-
standing of specific treatment preferences and overall dis-
ease comprehension of patients and caregivers will help to
identify potential gaps among important stakeholders
involved in the treatment decision making, improve the
transparency and openness of treatment decisions, and
ultimately empower patients to participate in the decisions
about their care, thereby improving treatment adherence
and optimizing outcomes.
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